Financial Data and Key Metrics Changes - The company ended 2025 with $1.25 billion in cash equivalents and marketable securities, with an anticipated minimum draw of $200 million from a strategic financing agreement, extending the runway into mid-2029 [40][41] - A strategic financing agreement with Sixth Street provides up to $500 million in long-term, non-dilutive capital to support the anticipated launch of risto-cel, enhancing financial flexibility [39][40] Business Line Data and Key Metrics Changes - The company is expanding its portfolio with a new development program for phenylketonuria (PKU) called BEAM-304, targeting the two most common mutations found in nearly half of PKU patients [9][19] - The risto-cel program is positioned as a potentially best-in-class autologous cell therapy for sickle cell disease, with significant demand observed in the market [39][73] Market Data and Key Metrics Changes - Approximately 20,000 individuals in the U.S. are living with PKU, representing a significant unmet need for new treatment options [10][19] - The market for risto-cel is characterized by a significant demand, with no refusals for payment reported despite high treatment costs [73] Company Strategy and Development Direction - The company aims to provide lifelong cures through base editing, focusing on one-time durable genetic medicines with predictable outcomes [5][6] - The modularity of the base editing platform allows for scalable development across multiple genetic diseases, with a focus on addressing additional mutations over time [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of base editing to deliver transformative therapies, emphasizing the importance of predictability in outcomes for patients and the healthcare ecosystem [7][42] - The company is well-positioned to realize the power of predictability across its growing portfolio, with plans to file the IND for BEAM-304 in 2026 [42][43] Other Important Information - The company has established a foundation of financial strength for sustainable growth, with a focus on efficient investments and building commercial capabilities ahead of the risto-cel launch [40][41] - The regulatory landscape is evolving, with the FDA showing openness to innovative trial designs that could accelerate the development of therapies for ultra-rare diseases [60][69] Q&A Session Summary Question: Regulatory path for multiple mutations and capital allocation - Management indicated that research efforts for additional mutations are already underway, with timelines expected to be fast due to the platform approach [48] - The strategic financing allows for flexibility in reallocating capital to additional liver-targeted indications [50] Question: Intellectual property and delivery mechanisms for BEAM-304 - The company has access to necessary IP, with pioneering work from Dr. Musunuru's lab contributing to the development of therapies for specific mutations [54] - BEAM-304 will utilize broadly similar lipid nanoparticle approaches as previous programs, ensuring consistency in delivery mechanisms [54] Question: FDA guidance on individualized therapy and mutation targeting - The FDA's draft guidance on individualized therapy is geared towards ultra-rare diseases, with ambiguity regarding the classification of PKU mutations [60][61] - The company plans to develop mutation-specific guide RNAs for each mutation within the same clinical program [68] Question: Responses of R408W carriers to current therapies and recruitment age range - R408W patients typically do not respond to existing therapies due to low enzyme activity, highlighting the need for new treatment options [84] - The FDA is showing collaboration in potentially allowing trials to include younger patient populations as data is gathered [83]

Financial Data and Key Metrics Changes - The company ended 2025 with $1.25 billion in cash equivalents and marketable securities, with an anticipated minimum draw of $200 million from a financing facility, extending the runway into mid-2029 [40][41] - A strategic financing agreement was announced, providing up to $500 million in long-term, non-dilutive capital to support the commercialization of risto-cel, an investigational autologous cell therapy for sickle cell disease [39] Business Line Data and Key Metrics Changes - The company is expanding its portfolio with a new development program for phenylketonuria (PKU) called BEAM-304, which targets multiple disease-causing mutations [9][10] - The PKU program aims to demonstrate the scalability of the company's platform and deliver transformative therapeutic options to patients [10][17] Market Data and Key Metrics Changes - Approximately 20,000 individuals in the U.S. are affected by PKU, with a significant unmet need for new treatment options [19][12] - The company is leveraging its proprietary lipid nanoparticle (LNP) delivery system to target hepatocytes in the liver for the treatment of PKU [20][22] Company Strategy and Development Direction - The company aims to provide lifelong cures for patients suffering from serious diseases through its base editing technology, which allows for precise genetic modifications [5][6] - The strategic focus includes accelerating paths to approval for its lead programs and expanding its pipeline to address additional mutations and metabolic disorders [42][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the predictability of outcomes from their base editing platform, which is expected to streamline R&D and improve confidence among stakeholders [7][42] - The company is well-positioned to realize the potential of its growing portfolio, with plans to file the IND for BEAM-304 in 2026 and report initial data for BEAM-301 in GSD Ia [43][40] Other Important Information - The company has established a foundation of financial strength for sustainable growth, with a focus on efficient investments and building commercial capabilities ahead of the anticipated risto-cel launch [41][39] - The regulatory landscape is evolving, with the FDA showing openness to innovative trial designs that could facilitate the development of therapies for ultra-rare diseases [64][70] Q&A Session Summary Question: Regulatory path for multiple mutations and capital allocation - Management indicated that research efforts for additional mutations are already underway, with expectations for fast timelines due to the platform approach [48] - The strategic financing enhances the company's ability to redirect capital towards the growth of its pipeline [50] Question: Intellectual property and delivery mechanisms for BEAM-304 - The company confirmed access to necessary IP and will utilize similar LNP approaches as in previous programs for BEAM-304 [55] Question: FDA's draft guidance on individualized therapy - Management discussed the ambiguity regarding what qualifies as ultra-rare diseases under the new framework, emphasizing the need for case-by-case discussions with the FDA [62][66] Question: Responses of R408W carriers to current therapies - Management noted that R408W patients typically do not respond to existing therapies due to the lack of residual enzyme activity, highlighting the need for new treatment options [87]

Financial Data and Key Metrics Changes - The company ended 2025 with $1.25 billion in cash equivalents and marketable securities, with an anticipated minimum draw of $200 million from a strategic financing agreement, extending the runway into mid-2029 [37][38] - A strategic financing agreement with Sixth Street provides up to $500 million in long-term, non-dilutive capital to support the anticipated launch of risto-cel, enhancing financial flexibility [36][37] Business Line Data and Key Metrics Changes - The company is expanding its portfolio with a new development program for phenylketonuria (PKU) called BEAM-304, targeting the two most common mutations found in nearly half of PKU patients [9][17] - The BEAM-304 program aims to leverage proprietary base editing technology and LNP delivery systems to correct disease-causing mutations in PKU patients [18][19] Market Data and Key Metrics Changes - Approximately 20,000 individuals in the U.S. are living with PKU, with significant unmet needs despite existing therapies [9][17] - The company is focusing on addressing a large population of PKU patients through innovative development approaches and regulatory pathways [9][18] Company Strategy and Development Direction - The company aims to provide lifelong cures for serious diseases through base editing, emphasizing predictable and reproducible outcomes [4][5] - The strategy includes leveraging modular technology to address multiple mutations and expand into other metabolic disorders over time [6][23] - The company is committed to developing a one-time treatment for as many PKU patients as possible, with plans to file the IND for BEAM-304 in 2026 [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the scalability of the base editing platform and its potential to deliver transformative therapies to patients [9][40] - The company is well-positioned to realize the power of predictability across its growing portfolio, with a focus on accelerating paths to approval for its lead programs [40][41] Other Important Information - The company has established a foundation of financial strength for sustainable growth, with a focus on building commercial capabilities ahead of the anticipated risto-cel launch [37][39] - The regulatory environment is evolving, with the FDA showing openness to innovative trial designs that could accelerate the development of gene editing therapies [60][68] Q&A Session Summary Question: Regulatory path for multiple mutations and capital allocation - Management indicated that research efforts for additional mutations are already underway, with expectations for faster timelines due to the platform approach [45][46] - The strategic financing allows for reallocation of capital to additional liver-targeted indications [48] Question: Intellectual property and delivery mechanisms for BEAM-304 - The company has access to necessary IP and will utilize similar LNP approaches as in previous programs [51][52] Question: FDA's draft guidance on individualized therapy - The FDA's guidance is geared towards ultra-rare diseases, with ambiguity regarding the classification of PKU mutations [60][61] Question: Responses of R408W carriers to current therapies - R408W patients typically do not respond to existing therapies due to low PAH enzyme activity, highlighting the need for new treatment options [86][87]